Biogen Idec, Pfizer, Bristol-Myers and Celgene are among companies awaiting US approval of key treatments.
The market is growing and the opportunities are there, but so are the risks.
The failure raises more questions about treatments designed to raise good cholesterol levels.
The biotech's partner says the vaccine didn't meet a study goal to show effectiveness. Stock drops almost 60%.
This biotech company's Soliris drug shows promise in treating several rare, life threatening diseases.
MSN Money's Charley Blaine discusses the sectors that could benefit from 4 more years of Obama.
The approval of the rheumatoid arthritis treatment will help douse recent concerns about its pipeline.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Plus, after much ado, Softbank is oh-so-close to acquiring Sprint.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Those shackled with student loan debt are increasingly being targeted by scams and shady companies promising relief.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.